On October 24, 2016 ApeX Therapeutics, a clinical stage biotechnology company focused on developing novel compounds to treat cancer, reported that it has changed its corporate name to Apexian Pharmaceuticals, Inc (Press release, Apexian Pharmaceuticals, OCT 24, 2016, View Source [SID1234517417]). As part of this name change, the company has also launched a new corporate website at www.ApexianPharma.com and a new Twitter handle @ApexianPharma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Now is the time to acknowledge that our key priorities are increasingly focused on advancing our innovative oncology molecules through the clinic" stated Steve Carchedi, President and CEO of Apexian Pharmaceuticals, "We are committed to developing innovative new medicines to extend and enhance the lives of cancer patients. The name change to Apexian Pharmaceuticals is indicative of the great progress we’ve made in advancing our APE1/Ref-1 targeted drug candidates. Specifically, our recent IND acceptance by the FDA for APX3330 highlights our focus on bringing safe and effective medicines into the clinic."

ApeX Therapeutics recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat late stage cancer.